<PAGE>
                      SECURITIES AND EXCHANGE COMMISSION

                            WASHINGTON, D.C. 20549

                                  FORM 10-QSB

(X)  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended  March 31, 1998
                                --------------

                                      OR

( )  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

                      Commission File Number:   1-10986

                                 MISONIX, INC.
            ------------------------------------------------------
            (Exact name of registrant as specified in its charter)

          New York                                             11-2148932
-------------------------------                            -------------------
(State or other jurisdiction of                            (I.R.S  Employer
incorporation or organization                              Identification No.)

1938 New Highway Farmingdale, N.Y.                                    11735
----------------------------------------                           ----------
(Address of principal executive offices)                           (Zip Code)

Registrant's telephone number, including area code...(516) 694-9555
                                                     --------------

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

      YES  X      NO
         -----      -----

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practical date:

                                                  Outstanding at
         Class of Common Stock                      May 1, 1998
         ---------------------                      -----------

            $.01 par value                           5,682,792

Transitional small business disclosure format (check one):

      YES         NO  X
         -----      -----

<PAGE>
                                 MISONIX, INC.
                                 -------------

Index

PART I.  FINANCIAL INFORMATION                                           Page

  Financial Statements:

    Consolidated Balance Sheet
     March 31, 1998(Unaudited)                                            3

    Consolidated Statements of Operations
     Nine months ended March 31, 1998
     and 1997 (Unaudited)                                                 4

    Consolidated Statements of Operations
     Three Months Ended March 31, 1998
     and 1997 (Unaudited)                                                 5

    Consolidated Statements of Cash Flows
     Nine months ended March 31, 1998
         and 1997 (Unaudited)                                             6

    Notes to Consolidated Financial Statements                            7

    Management's Discussion and Analysis of
     Financial Condition and Results of Operations                        8-9


PART II. OTHER INFORMATION

    Item 6:  Exhibits and Reports on Form 8-K                             10

    Signatures                                                            11

                                       2

<PAGE>
                                 MISONIX, INC.
                          CONSOLIDATED BALANCE SHEET
                                  (UNAUDITED)
                          ==========================

                                                                  March 31,
                     ASSETS                                         1998
                     ------                                     ------------
CURRENT:
  Cash and cash equivalents                                     $  3,161,909
  Investments held to maturity                                     8,361,207
  Accounts receivable, net of allowance
    for doubtful accounts of $106,118                              5,068,779
  Inventories (Note 3)                                             3,101,754
  Prepaid expenses and other current assets                          644,179
                                                                ------------

         TOTAL CURRENT ASSETS                                     20,337,828

PROPERTY, PLANT AND EQUIPMENT, at cost,
  less accumulated depreciation and
  amortization of $1,786,666
                                                                   1,222,518
PATENTS, at cost, less accumulated
 amortization of $6,733                                               37,091

GOODWILL, less accumulated amortization
 of $62,459                                                          400,126

OTHER                                                                 52,651
                                                                ------------

                                                                $ 22,050,214
                                                                ============
          LIABILITIES AND STOCKHOLDERS'
                    EQUITY
          -----------------------------
CURRENT:
  Note payable to bank                                          $    236,250
  Accounts payable                                                 1,937,212
  Accrued expenses and other current liabilities                   1,875,015
  Current maturities of capital lease obligations                    122,341
                                                                ------------

         TOTAL CURRENT LIABILITIES                                 4,170,818

CAPITAL LEASE OBLIGATIONS                                            104,331

DEFERRED INCOME                                                      845,872

MINORITY INTEREST (Note 1)                                           116,502

STOCKHOLDERS' EQUITY:
  Common stock, $.01 par value; shares authorized
    10,000,000; issued and outstanding 5,677,622                      56,776
  Additional paid-in capital                                      21,384,392
  Deficit                                                         (4,632,845)
  Cumulative foreign currency translation adjustment                   4,368
                                                                ------------

         TOTAL STOCKHOLDERS' EQUITY                               16,812,691
                                                                ------------

                                                                $ 22,050,214
                                                                ============

          See accompanying notes to consolidated financial statements

                                       3

<PAGE>
                                 MISONIX, INC.
                     CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
                     =====================================

                                                For the nine months ended
                                                        March 31,
                                            --------------------------------
                                                1998                1997
                                                ----                ----

NET SALES                                   $ 17,353,978        $ 11,505,876

COST OF GOODS SOLD                             8,105,262           5,233,925
                                            ------------        ------------

     Gross profit                              9,248,716           6,271,951
                                            ------------        ------------
OPERATING EXPENSES:
 Selling, general and
  administrative expenses                      5,281,296           3,903,953
 Research and development                        704,581             191,178
 Non-cash compensation charge                       --             4,359,600
                                            ------------        ------------

  Total operating expenses                     5,985,877           8,454,731
                                            ------------        ------------

  Income (Loss) from operations                3,262,839          (2,182,780)
                                            ------------        ------------
OTHER INCOME (EXPENSE):
 Interest income                                 343,165              75,982
 Interest expense                                (36,099)            (31,974)
 Option/license fees                              54,649             139,375
 Royalty income                                  386,302             121,314
 Foreign exchange gain (loss)                        191              (2,702)
 Miscellaneous (expense) income                   (2,085)              1,491
                                            ------------        ------------

Total other income                               746,123             303,486
                                            ------------        ------------
Income (Loss) before minority
 interest and income taxes                     4,008,962          (1,879,294)

Minority interest in net income of
 consolidated subsidiary                          (9,539)            (22,508)
                                            ------------        ------------

Income (Loss) before income taxes              3,999,423          (1,901,802)

Income taxes                                  (1,112,803)            (29,029)
                                            ------------        ------------

NET INCOME (LOSS)                           $  2,886,620        $ (1,930,831)
                                            ============        ============

NET INCOME (LOSS) PER SHARE - BASIC         $        .51        $       (.43)
                                            ============        ============

NET INCOME (LOSS) PER SHARE - DILUTED       $        .43        $       (.43)
                                            ============        ============

WEIGHTED AVERAGE COMMON SHARES                 5,675,392           4,541,171
                                            ============        ============
WEIGHTED AVERAGE COMMON SHARES AND
SHARE EQUIVALENTS OUTSTANDING                  6,667,868           4,541,171
                                            ============        ============

          See accompanying notes to consolidated financial statements

                                       4

<PAGE>
                                 MISONIX, INC.
                     CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
                     =====================================

                                              For the three months ended
                                                      March 31,
                                            ------------------------------
                                               1998               1997
                                               ----               ----

NET SALES                                   $ 6,516,470        $ 5,102,599

COST OF GOODS SOLD                            3,209,656          2,119,785
                                            -----------        -----------

     Gross profit                             3,306,814          2,982,814
                                            -----------        -----------
OPERATING EXPENSES:
 Selling, general and
  administrative expenses                     1,887,492          1,539,637
 Research and development                       256,878             92,816
 Non-cash compensation charge                      --            4,359,600
                                            -----------        -----------

  Total operating expenses                    2,144,370          5,992,053
                                            -----------        -----------

  Income (Loss) from operations               1,162,444         (3,009,239)
                                            -----------        -----------
OTHER INCOME (EXPENSE):
 Interest income                                 83,601             42,181
 Interest expense                               (11,291)           (10,916)
 Option/license fees                             18,964             15,938
 Royalty income                                 156,548            121,314
 Foreign exchange gain (loss)                    12,774            (20,532)
 Miscellaneous expense                             (610)              (658)
                                            -----------        -----------

Total other income                              259,986            147,327
                                            -----------        -----------
Income (Loss) before minority
 interest and income taxes                    1,422,430         (2,861,912)

Minority interest in net income of
 consolidated subsidiary                            (64)           (15,097)
                                            -----------        -----------

Income (Loss) before income taxes             1,422,366         (2,877,009)

Income taxes                                   (387,572)           (29,029)
                                            -----------        -----------

NET INCOME (LOSS)                           $ 1,034,794        $(2,906,038)
                                            ===========        ===========

NET INCOME (LOSS) PER SHARE - BASIC         $       .18        $      (.58)
                                            ===========        ===========

NET INCOME (LOSS) PER SHARE - DILUTED       $       .16        $      (.58)
                                            ===========        ===========

WEIGHTED AVERAGE COMMON SHARES                5,677,622          5,004,177
                                            ===========        ===========
WEIGHTED AVERAGE COMMON SHARES AND
SHARE EQUIVALENTS OUTSTANDING                 6,587,427          5,004,177
                                            ===========        ===========

         See accompanying notes to consolidated financial statements

                                       5

<PAGE>
                             MISONIX, INC.
                 CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (UNAUDITED)
                 =====================================

                                                      Nine months ended
                                                          March 31,
                                                ----------------------------
                                                    1998             1997
                                                    ----             ----
OPERATING ACTIVITIES:
  Net income (loss)                             $ 2,886,620      $(1,930,831)
  Adjustments to reconcile net income
    (loss)to net cash provided by
     operating activities:
      Depreciation and amortization                 275,498          141,828
      Minority interest in net income
       of subsidiary                                  9,539           22,508
      Foreign currency (loss) gain                   (2,476)           6,442
      Non-cash compensation charge                     --          4,359,600
      Changes in operating assets and
       liabilities:
        Accounts receivable                      (1,967,800)      (1,446,094)
        Inventory                                  (794,139)        (845,974)
        Prepaid expenses and other
         receivables                                (78,372)          69,973
        Deposits and other assets                    (2,094)         (25,526)
        Accounts payable and accrued
         expenses                                   226,889        1,843,112
                                                -----------      -----------
  Net cash provided by operating activities         553,665        2,195,038
                                                -----------      -----------

INVESTING ACTIVITIES:
  Sales of investments held to maturity           4,549,722          493,787
  Purchase of investments held to maturity       (6,543,334)      (6,831,942)
  Purchase of additional stock in Labcaire         (119,187)        (102,099)
  Acquisition of property and equipment            (523,195)        (212,168)
  Patent costs                                         --            (16,822)
                                                -----------      -----------
  Net cash used in investing activities          (2,635,994)      (6,669,244)
                                                -----------      -----------

FINANCING ACTIVITIES:
  Deferred income                                    98,821          368,625
  Repayment of note payable to bank                (262,765)         (22,754)
  Principal payments on capital lease
   obligation                                       (16,067)         (68,208)
  Exercise of employee stock options                 13,500           98,350
  Exercise of public warrants,
   less associated costs                               --          5,663,216
                                                -----------      -----------
  Net cash (used in) provided by
   financing activities                            (166,511)       6,039,229
                                                -----------      -----------

Effect of exchange rates                                919               67
                                                -----------      -----------

NET (DECREASE) INCREASE IN CASH                  (2,247,921)       1,565,090

CASH, beginning of period                         5,409,830        1,153,999
                                                -----------      -----------

CASH, end of period                             $ 3,161,909      $ 2,719,089
                                                ===========      ===========

          See accompanying notes to consolidated financial statements

                                       6

<PAGE>
                                 MISONIX, INC.
                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
          (Information with respect to interim periods is unaudited)
          ==========================================================

1. Basis of Presentation
   ---------------------

The consolidated financial statements of Misonix, Inc. include the accounts of
Misonix, Inc., its 86.7% owned subsidiary, Labcaire Systems Ltd. ("Labcaire"),
and its 100% owned subsidiary, Misonix, Ltd. All significant intercompany
balances and transactions have been eliminated.

2. Interim Periods
   ---------------

The financial statements for the nine months ended March 31, 1998 and 1997 are
unaudited but, in the opinion of management, include all adjustments,
consisting of normal recurring accruals, necessary for fair presentation of
financial position and results of operations. Results for the interim periods
are not necessarily indicative of the results for a full year. For further
information refer to the consolidated financial statements and footnotes
thereto included in the Company's annual report for the year ended June 30,
1997.

3. Inventories
   -----------

                  Inventories are summarized as follows:

                                        March 31,
                                          1998
                                       ----------
                   Raw materials       $1,815,763
                   Work-in-process        676,914
                   Finished goods         609,077
                                       ----------
                                       $3,101,754
                                       ==========

                                       7

<PAGE>
                                 MISONIX, INC
                    MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS
                 ---------------------------------------------

Results of Operations
---------------------

Nine months Ended March 31, 1998 and 1997
-----------------------------------------

Net Sales: Net sales of the Company's medical, scientific and industrial
products, increased $5,848,102 (50.8%) from $11,505,876 in the nine months
ended March 31, 1997 to $17,353,978 in the nine months ended March 31, 1998.
Parent Company sales for the nine months ended March 31, 1998 increased 70.4%
while sales at the Company's foreign subsidiary (Labcaire) increased 11.3% .
The Company's backlog of unfilled orders increased from $5,640,466 at March
31, 1997 to $10,423,936 at March 31, 1998. This increase is due to increasing
demand for the Company's scientific and industrial product lines and new
orders relative to the Company's medical devices.

Gross Profit: Gross profit decreased from 54.5% of sales in the nine months
ended March 31, 1997 to 53.3% of sales in the nine months ended March 31,
1998.

Selling, General and Administrative Expenses: Selling, general and
administrative expenses increased from $3,903,953 (33.9 % of sales) in the
nine months ended March 31, 1997 to $5,281,296 (30.4% of sales) in the nine
months ended March 31, 1998. This dollar increase relates to sales costs
associated with higher sales volume and hiring of additional administrative
and technical personnel, but reflects a percentage decrease due to higher
sales volume.

Research and Development Expenses: Medical product research and development
expenses were $50,999 in the nine months ended March 31, 1997 and $489,623 in
the nine months ended March 31, 1998. The increase in this area is due to
non-funded development costs associated with the Company's medical devices,
under its agreements with Medical Device Alliance, Inc. and U.S. Surgical
Corporation and new projects. Industrial product research and development
expenses were $140,179 in the nine months ended March 31, 1997 and $214,958 in
the nine months ended March 31, 1998. This increase is due to upgrades of fume
enclosure products and development work on new potential ultrasonic products.

Other Income (Expense): Other income during the nine months ended March 31,
1997 was $303,486. During the nine months ended March 31, 1998, other income
was $746,123. This increase was principally due to royalty income received
from Medical Device Alliance, Inc. on sales of the ultrasonic soft tissue
aspirator and interest income on investments.

Income Taxes: The Company is currently providing for income taxes at a rate of
approximately 28%. This rate reflects the benefit of deferred tax assets that
could not be used until the Company was profitable.

Liquidity and Capital Resources: At March 31, 1998, the Company had a cash
balance of $3,161,909 and investments held to maturity of $8,361,207 compared
with a cash balance of $2,719,089 and investments held to maturity of
$6,691,208 at March 31, 1997. This increase is due to royalties received from
Medical Device Alliance, Inc. and to cash flow from operations. Inventories
have increased from $2,082,636 at March 31, 1997 to $3,101,754 at March 31,
1998 reflecting, in part, the establishment of an inventory for the ultrasonic
soft tissue aspirator and the ultrasonic scalpel.

                                       8

<PAGE>
                                 MISONIX, INC
                    MANAGEMENT'S DISCUSSION AND ANALYSIS OF
           FINANCIAL CONDITION AND RESULTS OF OPERATIONS (continued)
           ---------------------------------------------------------

In addition, the Company has a revolving credit facility, which expires on
June 30, 1998, in the amount of $500,000 available to the Company for
short-term borrowings and letters of credit. Borrowings under the facility
bear interest at prime plus 2% and are collateralized by a security interest
in all assets of the Company. There are no outstanding borrowings under this
facility.

A revolving credit facility from a U.K. bank in the amount of approximately
$560,000 is available to Labcaire for short term borrowings. This facility
expires in August 1998 when all unpaid principal and interest is due. This
facility bears interest at U.K. prime plus 2% and is collateralized by a
security interest in all the assets of Labcaire and a guarantee by Labcaire's
directors. As of March 31, 1998, $236,250 was outstanding under this facility.

The Company believes that its existing capital resources will enable it to
maintain its current and planned operations for at least 12 months from the
date hereof.

Forward Looking Statements: This report contains certain forward looking
statements within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act, which are intended to be covered by the safe harbors
created thereby. Although the Company believes that the assumptions underlying
the forward looking statements contained herein are reasonable, any of the
assumptions could be inaccurate, and therefore, there can be no assurance that
the forward looking statements contained in this report will prove to be
accurate. Factors that could cause actual results to differ from the results
specifically discussed in the forward looking statements include, but are not
limited to , the absence of anticipated contracts, higher than historical
costs incurred in performance of contracts or in conducting other activities,
future economic, competitive and market conditions as well as management
business decisions.

                                       9

<PAGE>
                                 MISONIX, INC.

PART II. OTHER INFORMATION

Item 6:     Exhibits and Reports on Form 8-K
            --------------------------------

            There were no reports on Form 8-K filed during the quarter
            ended March 31, 1998.

                                      10

<PAGE>
                                  SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this Quarterly Report to be signed on its
behalf by the undersigned thereunto duly authorized.

Date: May 13, 1998
                                   MISONIX, INC.
                                   (Registrant)

                                   By: /s/ Joseph Librizzi
                                       --------------------------------------
                                       Joseph Librizzi
                                       President, Chief Executive Officer

                                   By: /s/ Peter Gerstheimer
                                       --------------------------------------
                                       Peter Gerstheimer
                                       Vice President and
                                       Chief Financial Officer

                                      11